Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pluri Inc. (PLUR : NSDQ)

• Company Description    Pluri Inc. is a biotechnology company. Its technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of medicine and climate change to food scarcity, animal cruelty and beyond. Pluri Inc., formerly known as Pluristem Therapeutics Inc., is based in HAIFA, Israel. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $2.37 Daily Weekly Monthly 20 Day Moving Average: 12,526 shares Shares Outstanding: 10.79 (millions) Market Capitalization: $25.62 (millions) Beta: 0.75 52 Week High: $5.96 52 Week Low: $2.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -30.99% -34.36% 12 Week -35.31% -40.20% Year To Date -20.60% -29.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5 - HAIFA,L3 3508409 ISR ph: 972-74-710-8600 fax: 972-74-710-8787 investor.relations@pluristem.com https://pluri-biotech.com

• General Corporate Information    Officers Yaky Yanay - Chief Executive Officer and President Zami Aberman - Chairman Liat Zalts - Chief Financial Officer and Treasurer Rami Levi - Director Alexandre Weinstein - Director Peer Information Pluri Inc. (CORR.) Pluri Inc. (RSPI) Pluri Inc. (CGXP) Pluri Inc. (BGEN) Pluri Inc. (GTBP) Pluri Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 72942G203 SIC: 2836 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/26 Next Expected EPS Date: 09/16/26 Share - Related Items Shares Outstanding: 10.79 Most Recent Split Date: 4.00 (0.13:1) Beta: 0.75 Market Capitalization: $25.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/16/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 16.11 EPS Growth vs. Year Ago Period: 41.49% vs. Previous Quarter: 22.54% Sales Growth vs. Year Ago Period: -60.89% vs. Previous Quarter: -15.66% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - -106.59 12/31/25 - -99.68 09/30/25 - -89.29 Current Ratio 03/31/26 - 0.33 12/31/25 - 0.43 09/30/25 - 0.53 Quick Ratio 03/31/26 - 0.33 12/31/25 - 0.43 09/30/25 - 0.53 Operating Margin 03/31/26 - -2,162.08 12/31/25 - -1,890.59 09/30/25 - -1,708.71 Net Margin 03/31/26 - -2,162.08 12/31/25 - -1,890.59 09/30/25 - -1,708.71 Pre-Tax Margin 03/31/26 - -1,696.48 12/31/25 - -1,466.43 09/30/25 - -1,271.58 Book Value 03/31/26 - -1.20 12/31/25 - -0.92 09/30/25 - -0.69 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©